Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03970447 · ClinicalTrials.gov registry record · Phase 2

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

A Phase 2 study of Glioblastoma, sponsored by Global Coalition for Adaptive Research.

Recruiting
Registry status
Phase 2
Development phase
1,280
Enrollment target
20
Study locations

NCT03970447 is a Phase 2 study of Glioblastoma that is actively recruiting participants, run by Global Coalition for Adaptive Research. The registered enrollment target is 1,280 participants, above the 102-participant average among 199 other Glioblastoma trials with a reported enrollment target (1155% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03970447, a Phase 2 study of Glioblastoma, is actively recruiting participants, sponsored by Global Coalition for Adaptive Research.

RECRUITING
Registry status
Phase 2
Development phase
1,280 participants
Enrollment target
20
Study locations

Study Summary

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

Conditions Studied

Glioblastoma

Interventions

  • DRUG Temozolomide
  • DRUG Regorafenib
  • RADIATION Radiation
  • DRUG Lomustine
  • DRUG Paxalisib

Study Locations (20)

California

  • University of California, San Diego - La Jolla
  • Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute - Los Angeles
  • University of California, Los Angeles - Los Angeles
  • St. Joseph Hospital - Orange
  • University of California, San Francisco - San Francisco
  • Stanford Cancer Center - Stanford

Florida

  • Mayo Clinic Cancer Center - Jacksonville
  • Sylvester Comprehensive Cancer Center - Miami
  • Moffitt Cancer Center - Tampa

Georgia

  • Piedmont Atlanta Hospital - Atlanta
  • Winship Cancer Institute of Emory University - Atlanta

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Minnesota

  • Abbott Northwestern Hospital - Minneapolis
  • Mayo Clinic Cancer Center - Rochester - Rochester

Alabama

  • University of Alabama at Birmingham - Birmingham

Colorado

  • University of Colorado Denver - Aurora

Connecticut

  • Yale Cancer Center / Smilow Cancer Hospital - New Haven

Trial Details

FieldValue
Enrollment Target 1,280 participants
Start Date 2019-07-30
Est. Completion 2030-06
Phase Phase 2

Sponsor

Global Coalition for Adaptive Research

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03970447

The ClinicalTrials.gov registry entry for NCT03970447 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 1,280 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 102-participant average among 199 other Glioblastoma trials with a reported enrollment target (1155% higher). The listed sponsor is Global Coalition for Adaptive Research, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which Temozolomide is the first listed.

NCT03970447 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT03970447 about?

NCT03970447 is a clinical study titled "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma". Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.

What is the current status of trial NCT03970447?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,280 participants. The study started on 2019-07-30. Estimated completion is 2030-06.

What conditions does trial NCT03970447 study?

This clinical trial studies the following conditions: Glioblastoma.

What interventions are being tested in trial NCT03970447?

The interventions under investigation include: Temozolomide (DRUG), Regorafenib (DRUG), Radiation (RADIATION), Lomustine (DRUG), Paxalisib (DRUG).

Who is sponsoring clinical trial NCT03970447?

This trial is sponsored by Global Coalition for Adaptive Research, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03970447 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glioblastoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.